Literature DB >> 10718987

Effect of a calcium sensitization modulator, Y-27632, on isolated human bronchus and pulmonary artery.

S Yamagata1, M Ichinose, H Sugiura, A Koarai, K Koike, K Shirato.   

Abstract

A recently developed pyridine derivative, Y-27632, has been reported to inhibit smooth muscle contraction by inhibiting Ca(2+)sensitization in animal experiments. However, the effect of this compound in human tissues has not yet been elucidated. The aim of the present study was to evaluate the effect of Y-27632 on human bronchi and pulmonary arteries. The tissues were obtained from lung cancer patients undergoing lung resection. Tissue responses were assessed by isometric tension measurement. Y-27632 relaxed the bronchi at basal tone with an IC(50)(concentration causing 50% relaxation of the maximal response) of 2.0+/-0.3x10(-6)M. Y-27632 also dose-dependently relaxed the bronchi precontracted by acetylcholine (ACh), histamine and neurokinin A, and the IC(50)was 3.0+/-0.4x10(-6), 2.5+/-0.5x10(-6)and 1.8 +/-0.3x10(-6)M, respectively. The dilatory effect of Y-27632 was significantly smaller in ACh-precontracted tissues compared with those of basal or histamine- and neurokinin A-induced precontracted bronchi (P<0.05). Further, Y-27632 showed an inhibitory effect on cholinergic nerve stimulation- and ACh-induced bronchial contraction to the same degree, suggesting that a modulatory effect of this compound on ACh release from nerve terminals was unlikely. Y-27632 also dilated the pulmonary arteries precontracted by phenylephrine (IC(50)= 1.6+/-0.1x10(-6)M). These data suggest that Y-27632 has a dilatory capacity on human bronchi as well as on pulmonary arteries. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10718987     DOI: 10.1006/pupt.1999.0227

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  6 in total

1.  Effect of bitter tastants on human bronchi.

Authors:  Alyn H Morice; Robert T Bennett; Mubarak A Chaudhry; Michael E Cowen; Steven C Griffin; Mahmoud Loubani
Journal:  Nat Med       Date:  2011-07-07       Impact factor: 53.440

2.  Suppression of airway hyperresponsiveness induced by ovalbumin sensitisation and RSV infection with Y-27632, a Rho kinase inhibitor.

Authors:  K Hashimoto; R S Peebles; J R Sheller; K Jarzecka; J Furlong; D B Mitchell; T V Hartert; B S Graham
Journal:  Thorax       Date:  2002-06       Impact factor: 9.139

3.  Low-level laser therapy (LLLT) attenuates RhoA mRNA expression in the rat bronchi smooth muscle exposed to tumor necrosis factor-alpha.

Authors:  Flávia Mafra de Lima; Jan M Bjordal; Regiane Albertini; Fábio V Santos; Flavio Aimbire
Journal:  Lasers Med Sci       Date:  2010-09       Impact factor: 3.161

4.  Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle.

Authors:  Alexandra Wibberley; Zunxuan Chen; Erding Hu; J Paul Hieble; Timothy D Westfall
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

5.  Receptor-independent activation of Rho-kinase-mediated calcium sensitisation in smooth muscle.

Authors:  Sinem Ayman; Pat Wallace; Chris P Wayman; Alan Gibson; Ian McFadzean
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

6.  Prenatal development is linked to bronchial reactivity: epidemiological and animal model evidence.

Authors:  Katharine C Pike; Shelley A Davis; Samuel A Collins; Jane S A Lucas; Hazel M Inskip; Susan J Wilson; Elin R Thomas; Harris A Wain; Piia H M Keskiväli-Bond; Cyrus Cooper; Keith M Godfrey; Christopher Torrens; Graham Roberts; John W Holloway
Journal:  Sci Rep       Date:  2014-04-17       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.